Literature DB >> 20842532

Biological pathways and genetic variables involved in pain.

Qiuling Shi1, Charles S Cleeland, Pål Klepstad, Christine Miaskowski, Nancy L Pedersen.   

Abstract

PURPOSE: This paper summarizes current knowledge of pain-related and analgesic-related pathways as well as genetic variations involved in pain perception and management.
METHODS: The pain group of the GENEQOL Consortium was given the task of summarizing the current status of research on genetic variations in pain and analgesic efficacy. This review is neither exhaustive nor comprehensive; we focus primarily on single-nucleotide polymorphisms.
RESULTS: Two categories of potential genetic pain-perception pathways were identified: neurotransmission modulators and mechanisms that affect inflammation. Four categories were identified for analgesic efficacy: genes related to receptor interaction, modulation of opioid effects, metabolism, and transport. Various genetic variations involved in these pathways are proposed as candidate genetic markers for pain perception and for individual sensitivity to analgesics.
CONCLUSIONS: Candidate gene association studies have been used to provide evidence for the genetic modulation of pain perception and response to analgesics. However, the nature and range of genetic modulation of pain is not well addressed due to the limited number of patients and the limited number of genes and genetic variants investigated in studies to date. Moreover, personalized analgesic treatments will require a more complete understanding of the effects of genetic variants and gene-gene interactions in response to analgesics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842532     DOI: 10.1007/s11136-010-9738-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  105 in total

1.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

Review 2.  Methadone--metabolism, pharmacokinetics and interactions.

Authors:  Anna Ferrari; Ciro Pio Rosario Coccia; Alfio Bertolini; Emilio Sternieri
Journal:  Pharmacol Res       Date:  2004-12       Impact factor: 7.658

3.  A neuroimmune interaction in painful peripheral neuropathy.

Authors:  G J Bennett
Journal:  Clin J Pain       Date:  2000-09       Impact factor: 3.442

4.  Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers.

Authors:  Jörn Lötsch; Nils von Hentig; Rainer Freynhagen; Norbert Griessinger; Michael Zimmermann; Alexandra Doehring; Maren Rohrbacher; Reinhard Sittl; Gerd Geisslinger
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

5.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

6.  Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration.

Authors:  Frédéric Aubrun; Olivier Langeron; Christophe Quesnel; Pierre Coriat; Bruno Riou
Journal:  Anesthesiology       Date:  2003-06       Impact factor: 7.892

7.  Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.

Authors:  Q Y Yue; J Hasselström; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

8.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  17 in total

Review 1.  Genetic Variants Associated with Cancer Pain and Response to Opioid Analgesics: Implications for Precision Pain Management.

Authors:  Gee Su Yang; Natalie M Barnes; Debra E Lyon; Susan G Dorsey
Journal:  Semin Oncol Nurs       Date:  2019-05-10       Impact factor: 2.315

2.  Biological pathways and genetic mechanisms involved in social functioning.

Authors:  Juan R Ordoñana; Meike Bartels; Dorret I Boomsma; David Cella; Miriam Mosing; Joao R Oliveira; Donald L Patrick; Ruut Veenhoven; Gert G Wagner; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2012-10-10       Impact factor: 4.147

Review 3.  Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update.

Authors:  Mirjam A G Sprangers; Melissa S Y Thong; Meike Bartels; Andrea Barsevick; Juan Ordoñana; Qiuling Shi; Xin Shelley Wang; Pål Klepstad; Eddy A Wierenga; Jasvinder A Singh; Jeff A Sloan
Journal:  Qual Life Res       Date:  2014-03-07       Impact factor: 4.147

Review 4.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Authors:  Mary Jeanne Kreek; Orna Levran; Brian Reed; Stefan D Schlussman; Yan Zhou; Eduardo R Butelman
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  Genetic variations underlying self-reported physical functioning: a review.

Authors:  Melissa S Y Thong; Mirjam A G Sprangers; Jeff A Sloan; Donald L Patrick; Ping Yang; Cornelis J F van Noorden
Journal:  Qual Life Res       Date:  2014-11-12       Impact factor: 4.147

6.  The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin.

Authors:  Jingwen Li; Peng Peng; Qi Mei; Shu Xia; Yijun Tian; Liya Hu; Yuan Chen
Journal:  Support Care Cancer       Date:  2018-03-03       Impact factor: 3.603

7.  Genetic variations and patient-reported quality of life among patients with lung cancer.

Authors:  Jeff A Sloan; Mariza de Andrade; Paul Decker; Jason Wampfler; Curtis Oswold; Matthew Clark; Ping Yang
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 8.  Biomarkers: symptoms, survivorship, and quality of life.

Authors:  Christine Miaskowski; Bradley E Aouizerat
Journal:  Semin Oncol Nurs       Date:  2012-05       Impact factor: 2.315

9.  Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes.

Authors:  Mirjam A G Sprangers; Jeff A Sloan; Andrea Barsevick; Cynthia Chauhan; Amylou C Dueck; Hein Raat; Quiling Shi; Cornelis J F Van Noorden
Journal:  Qual Life Res       Date:  2010-10-14       Impact factor: 4.147

Review 10.  Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine.

Authors:  Demissie Alemayehu; Joseph C Cappelleri
Journal:  Am Health Drug Benefits       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.